- Home
- SHLT vs AGEN Comparison
SHLT vs AGEN Comparison
Compare SHLT & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SHLT
- AGEN
- Stock Information
- Founded
- SHLT 1987
- AGEN 1994
- Country
- SHLT Israel
- AGEN United States
- Employees
- SHLT N/A
- AGEN N/A
- Industry
- SHLT Business Services
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SHLT Consumer Discretionary
- AGEN Health Care
- Exchange
- SHLT Nasdaq
- AGEN Nasdaq
- Market Cap
- SHLT 39.3M
- AGEN 38.1M
- IPO Year
- SHLT N/A
- AGEN 2000
- Fundamental
- Price
- SHLT $2.02
- AGEN $1.63
- Analyst Decision
- SHLT
- AGEN Buy
- Analyst Count
- SHLT 0
- AGEN 4
- Target Price
- SHLT N/A
- AGEN $8.00
- AVG Volume (30 Days)
- SHLT 9.5K
- AGEN 503.8K
- Earning Date
- SHLT 04-24-2025
- AGEN 05-06-2025
- Dividend Yield
- SHLT N/A
- AGEN N/A
- EPS Growth
- SHLT N/A
- AGEN N/A
- EPS
- SHLT N/A
- AGEN N/A
- Revenue
- SHLT $55,939,000.00
- AGEN $103,463,000.00
- Revenue This Year
- SHLT N/A
- AGEN $4.03
- Revenue Next Year
- SHLT N/A
- AGEN $5.57
- P/E Ratio
- SHLT N/A
- AGEN N/A
- Revenue Growth
- SHLT N/A
- AGEN N/A
- 52 Week Low
- SHLT $1.85
- AGEN $1.44
- 52 Week High
- SHLT $6.73
- AGEN $19.69
- Technical
- Relative Strength Index (RSI)
- SHLT 38.63
- AGEN 30.04
- Support Level
- SHLT $1.85
- AGEN $1.44
- Resistance Level
- SHLT $2.57
- AGEN $1.77
- Average True Range (ATR)
- SHLT 0.27
- AGEN 0.13
- MACD
- SHLT -0.04
- AGEN 0.04
- Stochastic Oscillator
- SHLT 22.67
- AGEN 38.78
About SHLT SHL Telemedicine Ltd
SHL Telemedicine Ltd develops and markets personal telemedicine solutions. It consists of the transmission of medical data by an individual, from a remote location to a medical call center through telecommunication networks. The company offers solutions to subscribing patients, health insurance companies, hospitals, clinics, and physicians. It provides healthcare professional solutions to patients suffering from congestive heart failure, chronic obstructive pulmonary disease, and readmission solutions for reducing heart-related readmissions. In addition, consumer solutions include cardiac monitoring services. The company's geographical segments Israel, Europe, and the rest of the world, out of which majority revenue comes from Israel.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).